RUNX1 and colorectal carcinoma: By utilizing specific inhibitors and activators, we highlighted the critical role of this pathway in mediating the effects of RUNX1 and MUC13 on β-catenin, providing deeper insights into the molecular mechanisms underlying CRC progression and potential therapeutic targets.